Neurocrine Biosciences published expert perspectives emphasizing hyperphagia in Prader-Willi syndrome (PWS) as a complex condition requiring integrated care. The experts highlight the multidimensional nature of hyperphagia, involving biological, behavioral, and environmental factors, and stress the importance of comprehensive assessment and management across a patient's lifespan. VYKAT XR (diazoxide choline) extended-release tablets, the first FDA-approved drug for hyperphagia in PWS, offer a significant advancement by complementing behavioral and environmental approaches. This integrated treatment approach aims to improve quality of life for patients and families, with ongoing research priorities including better clinical measures and care models.
Neurocrine Biosciences Inc (NBIX) shares are trading at USD 142.75 on Pluang as of Oct 23, 2026 03:25 WIB. The stock has gained 1.02% in the past day, reflecting positive investor sentiment. Its market capitalization stands at $14.36 billion, indicating its significant presence in the health sector.
